<DOC>
	<DOCNO>NCT01078974</DOCNO>
	<brief_summary>Pomalidomide newly discover drug may stop cancer cell grow abnormally . Pomalidomide may also stimulate immune system fight cancer cell possibly improve effectiveness dexamethasone rituximab fight Waldenstrom 's Macroglobulinemia ( WM ) cancer cell . This drug use multiple myeloma information research study suggest Pomalidomide may help reduce prevent growth cancer cell .</brief_summary>
	<brief_title>Pomalidomide , Dexamethasone Rituximab Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>- Participants give study drug-dosing calendar treatment cycle . Each treatment cycle last 28 day time participant take Pomalidomide orally day . Dexamethasone rituximab administer intravenously week 1 , 2 , 3 , 4 week 12 , 13 , 14 , 15 . - Since look high dose Pomalidomide combination dexamethasone rituximab administer safely without severe unmanageable side effect , everyone participates receive dose study drug . The dose participant get depend number participant enrol study well tolerated dos . - As long evidence participant 's Waldenstrom 's Macroglobulinemia progress , continue receive Pomalidomide 52 week . Participants ask return clinic follow-up test least every three month four year .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>18 year age old Able adhere study visit schedule protocol requirement Clinicopathological diagnosis Waldenstrom 's macroglobulinemia use consensus panel criterion CD20 positive base previous perform bone marrow immunohistochemistry flow cytometric analysis Meet criterion treat base consensus panel criterion Patient must receive least one previous therapy WM All previous cancer therapy , include radiation , hormonal therapy surgery , must discontinue least 4 week prior treatment study Measurable disease , define presence immunoglobulin M ( IgM ) paraprotein minimum IgM level 2 time ( great ) upper limit institution 's normal value require ECOG Performance status 0 , 1 2 Laboratory test within range outline protocol Disease free prior malignancy 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma situ cervix breast Screening patient high risk HBV HCV infection Willing able take aspirin alternate prophylactic anticoagulant Any serious medical condition , laboratory abnormality , psychiatric illness Pregnant lactating female Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Resistance intolerance prior rituximab therapy Previous therapy thalidomide lenalidomide Known hypersensitivity thalidomide , lenalidomide pomalidomide The development erythema nodosum characterize desquamate rash take similar drug Concurrent use anticancer agent treatment History noncompliance medical regimen Patients unwilling unable comply protocol Known positive HIV hepatitis infection Any history CVA ( Cerebral Vascular Accident/stroke ) clot Active DVT PE therapeutically anticoagulated NYHA classification III great heart failure Any patient unable ingest process pomalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>WM</keyword>
	<keyword>pomalidomide</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>rituximab</keyword>
</DOC>